Versor Investments LP Invests $316,000 in Zimmer Biomet Holdings, Inc. $ZBH

Versor Investments LP purchased a new position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 3,460 shares of the medical equipment provider’s stock, valued at approximately $316,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Creative Financial Designs Inc. ADV increased its holdings in shares of Zimmer Biomet by 77.3% during the 2nd quarter. Creative Financial Designs Inc. ADV now owns 1,422 shares of the medical equipment provider’s stock worth $130,000 after buying an additional 620 shares during the last quarter. Atria Investments Inc increased its holdings in shares of Zimmer Biomet by 5.1% during the 2nd quarter. Atria Investments Inc now owns 9,648 shares of the medical equipment provider’s stock worth $880,000 after buying an additional 470 shares during the last quarter. Live Oak Private Wealth LLC increased its holdings in shares of Zimmer Biomet by 1.2% during the 2nd quarter. Live Oak Private Wealth LLC now owns 53,977 shares of the medical equipment provider’s stock worth $4,923,000 after buying an additional 622 shares during the last quarter. Assetmark Inc. increased its holdings in shares of Zimmer Biomet by 83.0% during the 2nd quarter. Assetmark Inc. now owns 16,454 shares of the medical equipment provider’s stock worth $1,501,000 after buying an additional 7,462 shares during the last quarter. Finally, Premier Path Wealth Partners LLC increased its holdings in shares of Zimmer Biomet by 5.6% during the 2nd quarter. Premier Path Wealth Partners LLC now owns 13,166 shares of the medical equipment provider’s stock worth $1,201,000 after buying an additional 694 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Insider Activity at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,500 shares of the company’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $104.15, for a total value of $156,225.00. Following the completion of the sale, the senior vice president directly owned 6,833 shares of the company’s stock, valued at approximately $711,656.95. This represents a 18.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 1.39% of the company’s stock.

Zimmer Biomet Stock Performance

Shares of ZBH stock opened at $87.59 on Thursday. The company has a quick ratio of 0.96, a current ratio of 1.87 and a debt-to-equity ratio of 0.54. Zimmer Biomet Holdings, Inc. has a 52 week low of $85.84 and a 52 week high of $114.72. The stock has a market capitalization of $17.35 billion, a PE ratio of 21.31, a P/E/G ratio of 2.29 and a beta of 0.67. The firm has a 50 day moving average of $100.84 and a two-hundred day moving average of $97.60.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Wednesday, November 5th. The medical equipment provider reported $1.90 earnings per share for the quarter, beating analysts’ consensus estimates of $1.88 by $0.02. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The firm had revenue of $2 billion during the quarter, compared to analysts’ expectations of $2.01 billion. During the same period in the previous year, the company earned $1.74 earnings per share. Zimmer Biomet’s quarterly revenue was up 9.6% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th were issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date of this dividend was Tuesday, September 30th. Zimmer Biomet’s dividend payout ratio is presently 23.36%.

Wall Street Analyst Weigh In

ZBH has been the subject of a number of research analyst reports. Evercore ISI lowered their price objective on shares of Zimmer Biomet from $106.00 to $104.00 and set an “in-line” rating for the company in a research report on Tuesday, October 7th. Redburn Partners set a $130.00 target price on shares of Zimmer Biomet in a report on Thursday, September 18th. Roth Capital reiterated a “buy” rating on shares of Zimmer Biomet in a report on Thursday, August 7th. Johnson Rice set a $112.00 target price on shares of Zimmer Biomet in a report on Wednesday. Finally, Rothschild & Co Redburn initiated coverage on shares of Zimmer Biomet in a report on Thursday, September 18th. They issued a “buy” rating and a $130.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, eight have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $110.63.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.